Full Text View
Tabular View
No Study Results Posted
Related Studies
Perifosine + Sunitinib Malate for Patients With Advanced Cancers
This study has been terminated.
( AOI Pharma is reassessing the development strategy for perifosine. )
Study NCT00399152   Information provided by Keryx / AOI Pharmaceuticals, Inc.
First Received: November 9, 2006   Last Updated: February 17, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Renal Cancer
GIST
Additional conditions recognized in this trial
Carcinoma, Renal Cell
Kidney Neoplasms
More general conditions related to this trial
Adenocarcinoma
Carcinoma
Kidney Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
Perifosine
Sunitinib Malate
Additional drug interventions recognized in this trial
Sunitinib
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Keryx / AOI Pharmaceuticals, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services